Avacincaptad pegol - IVERIC bio
Alternative Names: Anti-C5 aptamer; ARC-1905; Avacincaptad pegol sodium; IZERVAY; ZimuraLatest Information Update: 09 Apr 2024
At a glance
- Originator Archemix Corporation
- Developer IVERIC bio
- Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dry age-related macular degeneration
- Phase III Stargardt disease
- Phase II Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
Most Recent Events
- 01 Apr 2024 FDA assigns PDUFA action date of 19/11/2024 for Avacincaptad pegol for Age-related macular degeneration (AMD)
- 01 Apr 2024 US FDA accepts sNDA for Avacincaptad pegol for geographic atrophy (GA) secondary to Dry age-related macular degeneration for review
- 24 Mar 2024 Phase-III clinical trials in Stargardt disease (Intravitreous), prior to March 2024 (Iveric Bio pipeline, March 2024)